Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Lacasse E, Brouillette E, Larose A, Parr TR Jr, Rubio A, Malouin F.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02181-18. doi: 10.1128/AAC.02181-18. Print 2019 Apr.

PMID:
30718255
2.

Tebipenem, the first oral carbapenem antibiotic.

Jain A, Utley L, Parr TR, Zabawa T, Pucci MJ.

Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522. doi: 10.1080/14787210.2018.1496821. Epub 2018 Jul 27. Review.

PMID:
30014729
3.

Treatment of Gram-negative bacterial infections by potentiation of antibiotics.

Zabawa TP, Pucci MJ, Parr TR Jr, Lister T.

Curr Opin Microbiol. 2016 Oct;33:7-12. doi: 10.1016/j.mib.2016.05.005. Epub 2016 May 25. Review.

PMID:
27232956
4.

Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins.

King AM, King DT, French S, Brouillette E, Asli A, Alexander JA, Vuckovic M, Maiti SN, Parr TR Jr, Brown ED, Malouin F, Strynadka NC, Wright GD.

ACS Chem Biol. 2016 Apr 15;11(4):864-8. doi: 10.1021/acschembio.5b00944. Epub 2016 Jan 14.

PMID:
26731698
5.

Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.

Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR, Parr TR Jr.

Antimicrob Agents Chemother. 2015 Oct;59(10):6501-5. doi: 10.1128/AAC.00981-15. Epub 2015 Aug 3.

6.

In vitro characterization of oritavancin clearance from human blood by low-flux, high-flux, and continuous renal replacement therapy dialyzers.

Kumar A, Mann HJ, Keshtgarpour M, Flynn MA, Deng H, Far AR, Parr TR, Moriarty SR.

Int J Artif Organs. 2011 Nov;34(11):1067-74. doi: 10.5301/ijao.5000008.

PMID:
22183520
7.

Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2012 Feb;39(2):159-62. doi: 10.1016/j.ijantimicag.2011.09.017. Epub 2011 Nov 8.

PMID:
22070858
8.

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.

9.

Assessment of oritavancin serum protein binding across species.

Arhin FF, Belley A, McKay G, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.

10.

Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.

Tanaka KS, Dietrich E, Ciblat S, Métayer C, Arhin FF, Sarmiento I, Moeck G, Parr TR Jr, Far AR.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1355-9. doi: 10.1016/j.bmcl.2010.01.006. Epub 2010 Jan 11.

PMID:
20097069
11.

Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2009 Dec;34(6):550-4. doi: 10.1016/j.ijantimicag.2009.08.012. Epub 2009 Oct 8.

PMID:
19818587
12.

Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):207-10. doi: 10.1016/j.diagmicrobio.2009.05.022.

PMID:
19748436
13.

Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.

Arhin FF, Kurepina N, Sarmiento I, Parr TR Jr, Moeck G, Kreiswirth B.

Int J Antimicrob Agents. 2010 Jan;35(1):93-4. doi: 10.1016/j.ijantimicag.2009.07.012. Epub 2009 Sep 9. No abstract available.

PMID:
19744836
14.

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF.

Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.

15.

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

J Antimicrob Chemother. 2009 Oct;64(4):868-70. doi: 10.1093/jac/dkp286. Epub 2009 Aug 4. No abstract available.

PMID:
19656783
16.

Vancomycin and oritavancin have different modes of action in Enterococcus faecium.

Patti GJ, Kim SJ, Yu TY, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J.

J Mol Biol. 2009 Oct 9;392(5):1178-91. doi: 10.1016/j.jmb.2009.06.064. Epub 2009 Jul 1.

17.

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.

18.

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

Belley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.

19.

Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis.

Reddy R, Dietrich E, Lafontaine Y, Houghton TJ, Belanger O, Dubois A, Arhin FF, Sarmiento I, Fadhil I, Laquerre K, Ostiguy V, Lehoux D, Moeck G, Parr TR Jr, Rafai Far A.

ChemMedChem. 2008 Dec;3(12):1863-8. doi: 10.1002/cmdc.200800255. No abstract available.

PMID:
18973169
20.

Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.

Houghton TJ, Tanaka KS, Kang T, Dietrich E, Lafontaine Y, Delorme D, Ferreira SS, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Far AR.

J Med Chem. 2008 Nov 13;51(21):6955-69. doi: 10.1021/jm801007z. Epub 2008 Oct 4.

PMID:
18834106
21.

Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.

Tanaka KS, Houghton TJ, Kang T, Dietrich E, Delorme D, Ferreira SS, Caron L, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Rafai Far A.

Bioorg Med Chem. 2008 Oct 15;16(20):9217-29. doi: 10.1016/j.bmc.2008.09.010. Epub 2008 Sep 9.

PMID:
18815051
22.

Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.

Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Oct;52(10):3820-2. doi: 10.1128/AAC.00361-08. Epub 2008 Jul 21.

23.

Newly defined in vitro quality control ranges for oritavancin broth microdilution testing and impact of variation in testing parameters.

Arhin FF, Tomfohrde K, Draghi DC, Aranza M, Parr TR Jr, Sahm DF, Moeck G.

Diagn Microbiol Infect Dis. 2008 Sep;62(1):92-5. doi: 10.1016/j.diagmicrobio.2008.05.009. Epub 2008 Jul 9.

PMID:
18614315
24.

Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.

Heine HS, Bassett J, Miller L, Bassett A, Ivins BE, Lehoux D, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 Sep;52(9):3350-7. doi: 10.1128/AAC.00360-08. Epub 2008 Jul 7.

25.

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.

26.

Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.

Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR Jr, Far AR, Schaefer J.

J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17.

27.

A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus.

Arhin F, Bélanger O, Ciblat S, Dehbi M, Delorme D, Dietrich E, Dixit D, Lafontaine Y, Lehoux D, Liu J, McKay GA, Moeck G, Reddy R, Rose Y, Srikumar R, Tanaka KS, Williams DM, Gros P, Pelletier J, Parr TR Jr, Far AR.

Bioorg Med Chem. 2006 Sep 1;14(17):5812-32. Epub 2006 Jun 8.

PMID:
16759869
28.

Triaminotriazine DNA helicase inhibitors with antibacterial activity.

McKay GA, Reddy R, Arhin F, Belley A, Lehoux D, Moeck G, Sarmiento I, Parr TR, Gros P, Pelletier J, Far AR.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1286-90. Epub 2005 Dec 15.

PMID:
16343901
29.

Systemic antibacterial activity of novel synthetic cyclic peptides.

Dartois V, Sanchez-Quesada J, Cabezas E, Chi E, Dubbelde C, Dunn C, Granja J, Gritzen C, Weinberger D, Ghadiri MR, Parr TR Jr.

Antimicrob Agents Chemother. 2005 Aug;49(8):3302-10.

30.

Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Boylan CJ, Campanale K, Iversen PW, Phillips DL, Zeckel ML, Parr TR Jr.

Antimicrob Agents Chemother. 2003 May;47(5):1700-6.

31.

Direct continuous method for monitoring biofilm infection in a mouse model.

Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, DeBoer M, Rubin M, Bellinger-Kawahara C, Parr TR Jr, Contag PR.

Infect Immun. 2003 Feb;71(2):882-90.

32.

4-Substituted D-glutamic acid analogues: the first potent inhibitors of glutamate racemase (MurI) enzyme with antibacterial activity.

de Dios A, Prieto L, Martín JA, Rubio A, Ezquerra J, Tebbe M, López de Uralde B, Martín J, Sánchez A, LeTourneau DL, McGee JE, Boylan C, Parr TR Jr, Smith MC.

J Med Chem. 2002 Sep 26;45(20):4559-70.

PMID:
12238935
33.

Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.

Rocchetta HL, Boylan CJ, Foley JW, Iversen PW, LeTourneau DL, McMillian CL, Contag PR, Jenkins DE, Parr TR Jr.

Antimicrob Agents Chemother. 2001 Jan;45(1):129-37.

34.

Discovery of MC-02,331, a new cephalosporin exhibiting potent activity against methicillin-resistant Staphylococcus aureus.

Hecker SJ, Cho IS, Glinka TW, Zhang ZJ, Price ME, Lee VJ, Christensen BG, Boggs A, Chamberland S, Malouin F, Parr TR, Annamalai T, Blais J, Bond EL, Case L, Chan C, Crase J, Frith R, Griffith D, Harford L, Liu N, Ludwikow M, Mathias K, Rea D, Williams R.

J Antibiot (Tokyo). 1998 Aug;51(8):722-34.

35.

Characterization of a rabbit model of staphylococcal osteomyelitis.

Smeltzer MS, Thomas JR, Hickmon SG, Skinner RA, Nelson CL, Griffith D, Parr TR Jr, Evans RP.

J Orthop Res. 1997 May;15(3):414-21.

PMID:
9246088
36.

Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative.

Paul TR, Venter A, Blaszczak LC, Parr TR Jr, Labischinski H, Beveridge TJ.

J Bacteriol. 1995 Jul;177(13):3631-40.

38.

Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-beta-D-glucan synthase.

Beaulieu D, Tang J, Yan SB, Vessels JM, Radding JA, Parr TR Jr.

Antimicrob Agents Chemother. 1994 May;38(5):937-44.

39.

Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-beta-D-glucan synthase.

Beaulieu D, Tang J, Zeckner DJ, Parr TR Jr.

FEMS Microbiol Lett. 1993 Apr 1;108(2):133-7.

PMID:
8486238
40.

Comparative analyses of Serratia spp. outer membrane porin proteins.

Hutsul J, Worobec E, Parr TR Jr, Becker GW.

Can J Microbiol. 1993 Apr;39(4):442-7.

PMID:
8388771
41.

Epidemiological typing of Moraxella catarrhalis by using DNA probes.

Beaulieu D, Scriver S, Bergeron MG, Low DE, Parr TR Jr, Patterson JE, Matlow A, Roy PH.

J Clin Microbiol. 1993 Mar;31(3):736-9.

42.

Comparison of the in vivo and in vitro nuclear magnetic resonance detection of trifluoromethyl penicillin V in rats.

Campbell GD, Ramaprasad S, Olsen KM, Tryka AF, Komoroski RA, Blaszczak LC, Parr TR Jr.

J Pharm Sci. 1993 Jan;82(1):48-51.

PMID:
8429491
43.

Modes of action and inhibitory activities of new siderophore-beta-lactam conjugates that use specific iron uptake pathways for entry into bacteria.

Brochu A, Brochu N, Nicas TI, Parr TR Jr, Minnick AA Jr, Dolence EK, McKee JA, Miller MJ, Lavoie MC, Malouin F.

Antimicrob Agents Chemother. 1992 Oct;36(10):2166-75.

44.

A new mercury-penicillin V derivative as a probe for ultrastructural localization of penicillin-binding proteins in Escherichia coli.

Paul TR, Halligan NG, Blaszczak LC, Parr TR Jr, Beveridge TJ.

J Bacteriol. 1992 Jul;174(14):4689-700.

45.

Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada.

Clairoux N, Picard M, Brochu A, Rousseau N, Gourde P, Beauchamp D, Parr TR Jr, Bergeron MG, Malouin F.

Antimicrob Agents Chemother. 1992 Jul;36(7):1504-13.

46.

The bacterial phosphotransferase system as a potential vehicle for the entry of novel antibiotics.

Parr TR Jr, Saier MH Jr.

Res Microbiol. 1992 Jun;143(5):443-7. Review.

PMID:
1448620
47.

Influence of growth media on Escherichia coli cell composition and ceftazidime susceptibility.

Malouin F, Chamberland S, Brochu N, Parr TR Jr.

Antimicrob Agents Chemother. 1991 Mar;35(3):477-83.

48.
49.

Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

Chamberland S, Malouin F, Rabin HR, Schollaardt T, Parr TR Jr, Bryan LE.

J Antimicrob Chemother. 1990 Jun;25(6):995-1010.

PMID:
2115039
50.

Outer membrane and porin characteristics of Serratia marcescens grown in vitro and in rat intraperitoneal diffusion chambers.

Malouin F, Campbell GD, Halpenny M, Becker GW, Parr TR Jr.

Infect Immun. 1990 May;58(5):1247-53.

Supplemental Content

Support Center